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Abstract
Background: Previous linkage and association studies have implicated the D-amino acid oxidase
activator gene (DAOA)/G30 locus or neighbouring region of chromosome 13q33.2 in the genetic
susceptibility to both schizophrenia and bipolar disorder. Four single nucleotide polymorphisms
(SNPs) within the D-amino acid oxidase (DAO) gene located at 12q24.11 have also been found to
show allelic association with schizophrenia.
Methods: We used the case control method to test for genetic association with variants at these
loci in a sample of 431 patients with schizophrenia, 303 patients with bipolar disorder and 442
ancestrally matched supernormal controls all selected from the UK population.
Results: Ten SNPs spanning the DAOA locus were genotyped in these samples. In addition three
SNPs were genotyped at the DAO locus in the schizophrenia sample. Allelic association was
detected between the marker rs3918342 (M23), 3' to the DAOA gene and both schizophrenia (χ2
= 5.824 p = 0.016) and bipolar disorder (χ2 = 4.293 p = 0.038). A trend towards association with
schizophrenia was observed for two other DAOA markers rs3916967 (M14, χ2 = 3.675 p = 0.055)
and rs1421292 (M24; χ2 = 3.499 p = 0.062). A test of association between a three marker haplotype
comprising of the SNPs rs778293 (M22), rs3918342 (M23) and rs1421292 (M24) and schizophrenia
gave a global empirical significance of p = 0.015. No evidence was found to confirm the association
of genetic markers at the DAO gene with schizophrenia.
Conclusion:  Our results provide some support for a role for DAOA in susceptibility to
schizophrenia and bipolar disorder.
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Introduction
The lifetime risk of developing schizophrenia or bipolar
disorder in the UK is 0.7% – 0.85% and 0.3% – 1.5%
respectively. Family, twin and adoption studies have
shown that there is a large genetic component to both dis-
orders. Multiply affected families are common, and there
is good evidence that the susceptibility genes for schizo-
phrenia can be transmitted by obligate carriers who have
an abnormal EEG, abnormal eye tracking and volumetric
deficits on MRI but have no formal mental illness [1].
Replicated evidence from genetic linkage studies has con-
firmed that multiple chromosomal loci are involved in
the heritability of both bipolar disorder and schizophre-
nia [2,3].
Evidence that a schizophrenia susceptibility locus maps to
chromosome 13q has been reported by several groups [4-
11], although not consistently demonstrated [2,12,13].
However such variability in the outcome of linkage stud-
ies is to be expected given genetic heterogeneity.
Several studies have also found linkage between bipolar
disorder (BPD) and markers on chromosome 13q. The
distribution of these linked markers would suggest at least
two distinct regions of linkage: 13q11-13q21 and 13q22-
13q32. The distal 13q22-13q32 region is more robustly
supported by the linkage data. A meta-analysis of linkage
scans in bipolar disorder found the strongest evidence for
a susceptibility locus on 13q at 79 cM [14]. Shaw et al sub-
sequently reported significant linkage with a lod score of
3.4 for markers mapping to this region [11]. In addition,
there have been a number of independent reports which
support linkage to the 13q22-13q32 region [15-18].
Chumakov and colleagues initially investigated the 13q34
region in schizophrenia using 191 SNPs spanning 5 Mb in
French Canadian and Russian samples [19]. Six markers
were found to be associated with schizophrenia in the
French Canadian sample, two of which were also associ-
ated in the Russian sample. This region contains two over-
lapping genes, DAOA (G72) and G30, which are
transcribed in opposing directions. The DAOA transcript
was found to express a primate specific 153 amino acid
protein that localises to the endoplasmic reticulum [19].
However, more recently it has been shown that the LG72
transcript codes for a mitochondrial protein [20]. No pro-
tein was identified for G30 in this study and it was postu-
lated that because G30 is transcribed on the opposite
strand it could act as a regulator for DAOA expression
[19]. Expression studies of DAOA in post-mortem brain
have found evidence for over expression in schizophrenic
brains compared to controls, but not for G30 [21]. A cor-
relation between DAOA and G30 expression was also
found supporting the notion that G30 acts as a regulator
of DAOA [21].
DAOA was found to interact directly with the enzyme D-
amino acid oxidase (DAO) leading to activation of DAO
[19]. However, this interaction could not be replicated by
Kvajo et al [20]. The DAO gene has been localised to chro-
mosome 12q. Four SNPs within the gene were also found
to be associated with schizophrenia in the French Cana-
dian but not in the Russian sample [19]. Logistic regres-
sion analysis demonstrated an interaction occurred
between SNPs at the two loci [19]. DAO is known to oxi-
dise D-serine, which is a powerful activator of the NMDA-
type glutamate receptor [22]. It was found that levels of D-
serine levels were higher in the serum of schizophrenic
patients compared to normal controls [23]. Elevated lev-
els of D-serine were also found in cerebrospinal fluid of
drug naïve patients with schizophrenia [24].
Hattori et al first reported association of variants at the
DAOA/G30 locus with bipolar disorder [25]. They exam-
ined 16 SNPs across a 157 kb region encompassing the
DAOA/G30 locus in two family-based samples. Five SNPs
showed individual association with BPD in the Clinical
Neurogenetics (CNG) sample.
Subsequently a number of groups have attempted to rep-
licate the associations between DAOA/G30 and schizo-
phrenia, BPD, a psychosis phenotype, and panic disorder.
A recent meta analysis of association findings for the
DAOA/G30 locus published up until April 2007 found
consistent evidence for association with markers at the
locus with schizophrenia. [26]. rs947267 (M18 SCZ in
Asians) and rs778293 (M22 SCZ in Asians) were associ-
ated with schizophrenia in Asian populations. rs1421292
(M24) was associated with schizophrenia in European
populations.
A number of studies were not included in the meta analy-
sis or have been published since April 2007. Hall et al,
who studied US and Afrikaans trios with schizophrenia,
found association between rs2391191 (M15) and schizo-
phrenia in the Afrikaans sample [27]. Korostishevsky et al
found suggestive evidence for association with schizo-
phrenia at the DAOA locus in a Palestinian-Arab sample
[28]. Fallin et al used an Israeli sample of 337 BPD trios
and 274 schizophrenia trios. They showed overlapping
suggestive evidence of association with DAOA/G30 for
both disorders. They also found evidence for association
of DAO with BPD [29]. Shin et al found association of
rs947267 (M18) and rs778294 (M19) with schizophrenia
in a Korean case control sample [30]. Shinkai et al
reported association of rs746187 (M7) and rs947267
(M18) with schizophrenia in their case control sample.
They also found over transmission of alleles to affected
offspring with markers rs746187 (M7), rs3918342 (M23)
and rs1421292 (M24) in their family based sample [31].
Corvin et al reported association with markers at both theBehavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
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DAO and DAOA loci in an Irish schizophrenia case con-
trol sample [32]. Association was detected with the DAOA
markers rs3916965 (M12 p = 0.005) and rs2391191 (M15
p = 0.01); and with the DAO markers rs2111902 (M4 p =
0.02) and rs391834 (M5 p = 0.003). A logistic regression
based interaction analysis demonstrated evidence for epi-
static interaction between the DAOA marker rs3916965
(M21) and the DAO marker rs3918346 (M5), p = 0.008.
Of note these were not the same markers found to interact
in the Chumakov (2002) study [19]. Prata et al found no
evidence for single marker association with bipolar disor-
der using markers at DAOA and DAO in a case control
sample. They did however find some evidence for haplo-
type association at both loci [33].
A UK study looked at DAOA polymorphisms in both
schizophrenia and bipolar samples [34]. Association was
detected in the bipolar sample but not in the schizophre-
nia sample [34]. The authors went on to perform sub-
analysis across traditional diagnostic boundaries. More
significant associations were found when schizophrenia
patients with a history of major mood disorder were
added to the bipolar group. Shultze et al also attempted a
phenotypic dissection of their bipolar sample. They con-
cluded that the DAOA association was specifically linked
to BPD patients with persecutory delusions [35]. The
authors also reported an independent haplotypic, but not
allelic replication, in a Polish sample[35].
However not all studies have supported the association of
DAOA with schizophrenia [36,37]. Genome wide associ-
ation studies of schizophrenia published to date [38-43]
do not further implicate DAOA or DAO. Two SNPs,
rs1981272 (p = 0.0315) and rs9519697 (p = 0.0445), in
the DAOA gene region were found to be associated in the
WTCCC bipolar disorder genome wide association study
[44]. However there is sample overlap between this study
and the studies by Williams et al [34] and Prata et al [33].
No SNPs in the DOAO or DAO regions were found to be
associated with bipolar disorder in a meta analysis of
genome wide association data that included amongst oth-
ers the UCL samples described here and the WTCCC sam-
ples [45].
In this investigation we test for allelic and haplotypic asso-
ciation between markers at the DAOA locus in our schiz-
ophrenia and BPD samples. Additionally we test for
association of markers within the DAO locus with schizo-
phrenia.
Materials and methods
Sample
The case and control samples were recruited from London
and South England and consist of 431 volunteers with
schizophrenia, 303 volunteers with bipolar disorder and
443 control volunteers. For all groups subjects were
included only if three out of four grandparents were of
English, Irish, Welsh or Scottish descent.
"Volunteers were excluded if the other grandparent was of
non Caucasian European ancestry (based on the EU coun-
tries before the 2004 enlargement). UK National Health
Service multicentre and local research ethics approval was
obtained and all subjects signed an approved consent
form after reading an information sheet. All volunteers
with schizophrenia or bipolar disorder were interviewed
using the SADS-L [46]. All cases were selected on the basis
of having a primary clinical diagnosis of schizophrenia or
bipolar disorder and were then formally diagnosed if they
achieved the probable level of the Research Diagnostic
Criteria (RDC). Research subjects with brain damage prior
to the onset of the disorder were excluded. The "supernor-
mal" control subjects were also interviewed with the ini-
tial clinical screening questions of the SADS-L and
selected on the basis of not having a family history of
schizophrenia, alcoholism or bipolar disorder and for
having no personal history of any RDC defined mental
disorder.
Genomic DNA was extracted from frozen whole blood
samples using a standard cell lysis, proteinase K digestion,
phenol/chloroform, ethanol precipitation method. DNA
samples were quantified using picogreen.
Genotyping
Eleven SNPs at the DAOA locus were genotyped in the
BPD, schizophrenia and control samples. Three SNPs
were genotyped at the DAO locus in the schizophrenia
and the control samples. We attempted to assay all four
DAO SNPs described in the original Chumakov study, but
we were unable to develop an assay for the SNP MDAO7
with the technology available to us [19]. SNPs rs1341402,
rs2391191 (M15), rs1935062, rs947267 (M18),
rs778294 (M19), rs954581, rs778293 (M22), rs3918342
(M23), rs1421292 (M24) as well as the 3 DAO SNPs
(MDAO4, MDAO5 and MDAO6) were genotyped by KBi-
osciences (Hertfordshire, UK) which employs the KASPar
SNP genotyping method. Duplicate DNA samples were
incorporated on the microtitre plates for 17% of individ-
uals in order to detect error and confirm the reproducibil-
ity of genotypes. SNPs rs3916965 (M12) and rs3916967
(M14), were typed using Pyrosequencing according to
manufacturer's instructions (Biotage, Uppsala, Sweden).
Statistical analysis
In order to confirm that the samples were genetically well
matched, fifteen genetic markers at chromosomal loci,
thought not to be involved in schizophrenia or bipolar
disorder were genotyped in a subset of the sample (200
cases and 300 controls) and analyzed to detect geneticBehavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
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Table 1: Allele Frequencies and tests of association with schizophrenia and bipolar disorder on chromosome 13q33.2 at the DAOA 
locus.
Marker Position on chromosome 13
(bp)
Allele Counts χ2 (1 d.f.) p value
rs3916965 (M12) 104901361 C T
Controls 391 237
Schizophrenia 309 223 2.101 0.147
rs3916967 (M14) 104915349 A G
Controls 397 235
Schizophrenia 306 228 3.675 0.055
rs1341402 104913510 C T
Controls 138 488
Bipolar 126 472 0.172 0.679
rs2391191 (M15) 104917447 A G
Controls 326 544
Schizophrenia 305 473 0.521 0.470
Bipolar 246 360 1.468 0.226
rs1935062 104926137 A C
Controls 416 210 0.172 0.679
Bipolar 401 205 0.011 0.917
rs947267 (M18) 104937663 A C
Controls 502 368
Schizophrenia 454 348 0.203 0.652
Bipolar 358 246 0.362 0.548
rs778294 (M19) 104940236 C T
Controls 639 237
Schizophrenia 593 211 0.141 0.707
Bipolar 438 166 0.033 0.856
rs954581 104950267 C T
Controls 102 518
Bipolar 123 479 3.221 0.073
rs778293 (M22) 104967200 A G
Controls 522 499
Schizophrenia 338 293 0.93 0.335
rs3918342 (M23) 104983750 C T
Controls 444 412
Schizophrenia 358 422 5.824 0.016
Bipolar 281 325 4.293 0.038
Combined 639 747 7.044 0.008
rs1421292 (M24) 104996236 A T
Controls 462 398
Schizophrenia 388 402 3.499 0.062
Bipolar 301 305 2.337 0.126
Combined 689 707 4.059 0.044Behavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
Page 5 of 10
(page number not for citation purposes)
heterogeneity between cases and controls using Wright's
Fst statistic with the program GDA [47]. No evidence for
heterogeneity was observed.
In addition, a statistical test (CHECKHET) for detecting
subjects with an atypical genetic background was
employed [48].
Prior to association analysis, the program SCANGROUP
(which is a subprogram of GENECOUNTING) was used
to test whether there were differences in the haplotype fre-
quencies between the 96 well microtitre plates. This may
identify errors due to data entry or plate inversion. Once
data was error checked, the data was analysed to confirm
Hardy-Weinberg equilibrium (HWE). Markers with a lack
of HWE in the control group were rejected and genotyping
was repeated. Single marker allelic association analyses
were performed using standard chi-squared tests. The gen-
otypes were analysed for marker-to-marker linkage dise-
quilibrium (LD) using GENECOUNTING/LDPAIRS. This
computes D' and r2 tests of LD and maximum likelihood
estimates of haplotype frequencies from phase unknown
case control data [49,50]. For the DAOA locus all data
obtained from patients with schizophrena, BPD and con-
trols were used to calculate LD. We genotyped markers
within the DAO locus in our schizophrenia and control
sample and used this data to calculate LD values.
Two and three marker haplotypic association was tested.
The significance of any overall haplotype association was
computed using a permutation test [49-51].
Results
All the data collected in this study was found to be in
Hardy Weinberg equilibrium and free from systematic
errors.
Table 1 displays the allele frequencies and tests of associ-
ation for the SNP markers genotyped at the DAOA locus
schizophrenic patients, bipolar disorder patients and con-
trols. The results for the DAO SNPs are found in table 2.
Allelic association was detected with both diseases with
marker rs3918342 (M23; schizophrenia χ2 = 5.824 p =
0.016; bipolar disorder χ2 = 4.293 p = 0.038; combined χ2
= 7.044 p = 0.008). A trend toward association with schiz-
ophrenia was observed with rs3916967 (M14; χ2 = 3.675
p = 0.055) and rs1421292 (M24; χ2 = 3.499 p = 0.0615).
For marker rs1421292 (M24) a nominally significant
association was also detected in the combined analysis (χ2
= 4.06 p = 0.044).
Pair-wise linkage disequilibrium (LD) was calculated
between all pairs of markers at the DAOA locus using
GENECOUNTING for the combined data from the schiz-
ophrenia, BPD and control samples (see Figure 1). Mark-
ers rs3916965 (M12) to rs778294 (M19) formed an LD
block defined with a solid spine of LD with a D' >0.8.
Markers rs778293 (M22), rs3918342 (M23) and
rs1421292 (M24) also formed a separate LD block. Tests
of haplotypic association with schizophrenia with mark-
ers rs778293 (M22), rs3918342 (M23) and rs1421292
(M24) were positive (global permutation p = 0.018). The
haplotype most likely to increase the risk of schizophrenia
comprised alleles G, T, A with estimated frequencies of
1.8% in controls and 3.6% in cases of schizophrenia, the
results of this analysis are shown in table 3. Haplotype
analysis of data from the BPD sample did not show evi-
dence for association.
Association of rs3918342 (M23) using the following case
definition was tested: schizophrenia with mood disorders,
schizophrenia with mood disorders and BPD combined,
BPD with persecutory delusions, and schizophrenia and
BPD with persecutory delusions. Nominal association
was found with the schizophrenia with mood disorders
Table 2: Allele Frequencies and tests of association with schizophrenia at the DAO locus on chromosome 12q24.11 in schizophrenia 
patients and controls.
Marker Position on chromosome 12
(bp)
Allele Counts χ2 (1 d.f.) p value
rs2111902 (MDAO-4) 107781213 A C
Controls 604 266
Schizophrenia 522 226 0.025 0.875
rs3918346 (MDAO-5) 107784350 C T
Controls 655 221
Schizophrenia 601 181 0.976 0.323
rs3741775 (MDAO-6) 107786069 T G
Controls 483 379
Schizophrenia 418 354 0.587 0.444Behavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
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Tests of linkage disequilibrium using D' between adjacent markers within the DAOA/G30 gene locus chromosome 13q33.2 Figure 1
Tests of linkage disequilibrium using D' between adjacent markers within the DAOA/G30 gene locus chromo-
some 13q33.2.Behavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
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and BPD combined phenotype (χ2 = 4.696 p = 0.030) and
the schizophrenia and BPD with persecutory delusions
phenotype (χ2 = 3.968 p = 0.046).
We did not find statistically significant association
between the three markers at the DAO locus and schizo-
phrenia (Table 2). D' values for DAO are displayed in Fig-
ure 2.
Discussion
Allelic association was detected between one DAOA
marker (rs3918342, M23) and schizophrenia in our sam-
ple. The T allele at rs3918342 (M23) was associated with
schizophrenia in our study. This is the same allele that was
found to be associated in the study of Chumakov et al
[19]. However it should be stated that association
between rs3918342 and schizophrenia was not found in
the meta-analysis of DAOA studies [26]. A trend towards
association with schizophrenia was found with the
marker rs1421292 (M24). The T allele at rs1421292
(M24) was more common in schizophrenic patients than
controls. This is the same allele that was found to be asso-
ciated in the study of Chumakov et al [19] and the meta-
analysis[26]. These findings were supported by haplotypic
association.
A modest association of the marker rs3918342 (M23) was
also found with bipolar disorder. This provides some sup-
port for the involvement of DAOA in the aetiology of
bipolar disorder. It should however, also be noted that
rs3918342 (M23) is located approximately 50 kb from
the 3' end of DAOA and that the LD structure shown in
figure 1 suggests that this SNP may have little relevance to
unknown functional variants located within the gene.
Three markers were genotyped at the DAO locus in our
schizophrenia sample. These did not provide evidence for
allelic or haplotypic association with the disease.
Table 3: Estimated haplotype frequencies in controls and cases 
of schizophrenia with markers rs778293 (M22), rs3918342 (M23) 
and rs1421292 (M24) on chromosome 13q33.2 at the DAOA 
locus.
Alleles Estimated frequencies
M22 M23 M24 Controls Schizophrenia
A C A 0.145 0.122
A T T 0.456 0.502
G C A 0.371 0.330
G T A 0.018 0.036
Tests of linkage disequilibrium using D' between adjacent  markers within the DAO gene locus chromosome 12q24.11 Figure 2
Tests of linkage disequilibrium using D' between 
adjacent markers within the DAO gene locus chro-
mosome 12q24.11.Behavioral and Brain Functions 2009, 5:28 http://www.behavioralandbrainfunctions.com/content/5/1/28
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In light of the previous findings with DAOA and DAO
using the same markers and with the level of LD between
markers no correction for multiple testing has been
applied to the data presented because the appropriate
method for correcting these analyses is not clear.
Our findings point to a role for DAOA in both schizophre-
nia and bipolar disorder. However it is evident that this
locus can account for only a small proportion of the
genetic susceptibility to these disorders.
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